MersV1, Main, Curation, bibRecord, 001094

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Identifieur interne : 001094 ( Main/Curation ); précédent : 001093; suivant : 001095

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Auteurs : Jean-François Rossignol

Source :

Journal of Infection and Public Health [ 1876-0341 ] ; 2016.

RBID : PMC:7102735

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Essais cliniques comme sujet, Humains, Infections à coronavirus (traitement médicamenteux), Modèles animaux de maladie humaine, Réplication virale (), Thiazoles (pharmacologie), Thiazoles (usage thérapeutique).
MESH :
- pharmacologie : Antiviraux, Thiazoles.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Antiviraux, Thiazoles.
- Animaux, Coronavirus du syndrome respiratoire du Moyen-Orient, Essais cliniques comme sujet, Humains, Modèles animaux de maladie humaine, Réplication virale.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Clinical Trials as Topic, Coronavirus Infections (drug therapy), Disease Models, Animal, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), Thiazoles (pharmacology), Thiazoles (therapeutic use), Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents, Thiazoles.
- chemical , therapeutic use : Antiviral Agents, Thiazoles.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Replication.
- drug therapy : Coronavirus Infections.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.

Abstract

Summary

Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735

DOI: 10.1016/j.jiph.2016.04.001
PubMed: 27095301
PubMed Central: 7102735

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E38
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000E38
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A56
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001157
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001157
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002A36
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001584
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001584
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001584
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001098

Links to Exploration step

PMC:7102735

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27095301</idno>
<idno type="pmc">7102735</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735</idno>
<idno type="RBID">PMC:7102735</idno>
<idno type="doi">10.1016/j.jiph.2016.04.001</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E38</idno>
<idno type="wicri:Area/Pmc/Curation">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E38</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A56</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A56</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:27095301</idno>
<idno type="wicri:Area/PubMed/Corpus">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001157</idno>
<idno type="wicri:Area/PubMed/Curation">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001157</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A36</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A36</idno>
<idno type="wicri:Area/Ncbi/Merge">001584</idno>
<idno type="wicri:Area/Ncbi/Curation">001584</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001584</idno>
<idno type="wicri:doubleKey">1876-0341:2016:Rossignol J:nitazoxanide:a:new</idno>
<idno type="wicri:Area/Main/Merge">001098</idno>
<idno type="wicri:Area/Main/Curation">001094</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</analytic>
<series><title level="j">Journal of Infection and Public Health</title>
<idno type="ISSN">1876-0341</idno>
<idno type="eISSN">1876-035X</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (physiology)</term>
<term>Thiazoles (pharmacology)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Réplication virale ()</term>
<term>Thiazoles (pharmacologie)</term>
<term>Thiazoles (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Modèles animaux de maladie humaine</term>
<term>Réplication virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Summary</title>
<p>Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits <italic>in vitro</italic>
 activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include <italic>in vitro</italic>
 mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name>
</author>
<author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name>
</author>
<author><name sortKey="Arabi, Y" uniqKey="Arabi Y">Y. Arabi</name>
</author>
<author><name sortKey="Alotaibi, B" uniqKey="Alotaibi B">B. Alotaibi</name>
</author>
<author><name sortKey="Rao, M" uniqKey="Rao M">M. Rao</name>
</author>
<author><name sortKey="Mccloskey, B" uniqKey="Mccloskey B">B. McCloskey</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Chiappa, L" uniqKey="Chiappa L">L. Chiappa</name>
</author>
<author><name sortKey="Ciucci, A" uniqKey="Ciucci A">A. Ciucci</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Belardo, G" uniqKey="Belardo G">G. Belardo</name>
</author>
<author><name sortKey="Cenciarelli, O" uniqKey="Cenciarelli O">O. Cenciarelli</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lam, K K Y" uniqKey="Lam K">K.K.Y. Lam</name>
</author>
<author><name sortKey="Zheng, X" uniqKey="Zheng X">X. Zheng</name>
</author>
<author><name sortKey="Forestieri, R" uniqKey="Forestieri R">R. Forestieri</name>
</author>
<author><name sortKey="Balgi, A D" uniqKey="Balgi A">A.D. Balgi</name>
</author>
<author><name sortKey="Nodwell, M" uniqKey="Nodwell M">M. Nodwell</name>
</author>
<author><name sortKey="Volett, S" uniqKey="Volett S">S. Volett</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Romark Laboratories" uniqKey="Romark Laboratories">Romark Laboratories</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name>
</author>
<author><name sortKey="Forrest, J C" uniqKey="Forrest J">J.C. Forrest</name>
</author>
<author><name sortKey="Zhang, X" uniqKey="Zhang X">X. Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hong, S K" uniqKey="Hong S">S.K. Hong</name>
</author>
<author><name sortKey="Kim, H G" uniqKey="Kim H">H.G. Kim</name>
</author>
<author><name sortKey="Chong, C S" uniqKey="Chong C">C.S. Chong</name>
</author>
<author><name sortKey="Choi, I S" uniqKey="Choi I">I.S. Choi</name>
</author>
<author><name sortKey="Lee, J B" uniqKey="Lee J">J.B. Lee</name>
</author>
<author><name sortKey="Park, S Y" uniqKey="Park S">S.Y. Park</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Haffizulla, J" uniqKey="Haffizulla J">J. Haffizulla</name>
</author>
<author><name sortKey="Hartman, A" uniqKey="Hartman A">A. Hartman</name>
</author>
<author><name sortKey="Hoppers, M" uniqKey="Hoppers M">M. Hoppers</name>
</author>
<author><name sortKey="Resnick, H" uniqKey="Resnick H">H. Resnick</name>
</author>
<author><name sortKey="Samudrala, S" uniqKey="Samudrala S">S. Samudrala</name>
</author>
<author><name sortKey="Ginocchio, C" uniqKey="Ginocchio C">C. Ginocchio</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001094 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001094 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:7102735
   |texte=   Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:27095301" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki